Kodiak Sciences Inc.
Kodiak Sciences Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 9.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 8 concluded trials, 38% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 13, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| February 15, 2027 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | Trial Milestone | Phase 3 |
| April 15, 2027 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | Trial Milestone | Phase 3 |
| August 31, 2028 | A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO | Trial Milestone | Phase 3 |
Track KOD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KOD in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.